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Abstract 
Review on SLC22A3, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
SLC22A3; Hepatocellular carcinoma; Prostate 
cancer; Renal cell carcinoma; Colon cancer 
Identity 
Other names: EMT, OCT3 
HGNC (Hugo): SLC22A3 
Location: 6q25.3 
Location (base pair) 
Starts at 160769405 and ends at 160873611 bp 
Note 
The length of SLC22A3 gene is 3.499 base-pair (bp) 
with an open reading frame of 1.653 bp (Verhaagh 
et al., 1999). Genes encoding the  
members of solute carrier family 22a locate at human 
chromosome 6q26-q27 as a conserved gene cluster 
between apolipoprotein(a), APO(a)-like gene and 
tumor suppressor gene IGF2R (Figure 1; Verhaagh 
et al., 1999; Tregouet et al., 2009; Heise et al., 2012). 
DNA/RNA 
Note 
SLC22A3 is one of three members of cation 
transporter genes located on chromosome 6. 
SLC22A3 is involved in the transportation of a 
variety of organic cations. Organic transporters have 
been included into the family of solute carrier 
proteins due to their homologies and third member 
of this family which was previously called organic 
cation transporter 3, OCT3, and the extraneuronal 
monoamine transporter, EMT, renamed as 
SLC22A3 (Verhaagh et al., 1999; Wieland et al., 
2000; Verhaagh et al., 2001). 
Figure 1. Localization of human SLC22A3 gene on chromosome 6q26-q27 (as depicted in Verhaagh et al., 2009).IMAGE_FISH 
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Figure 2. Gene structure of human SLC22A3 (as depicted inWieland et al., 2000). 
 
Description 
The SLC22A3 gene consists of 11 exons and 10 
introns, and encodes a 551 amino acid long 
membrane protein that comprises 12 predicted ?-
helical transmembrane domains (TMDs). 
Intron/exon boundaries have the conserved gt/ag 
consensus splice sites (Figure 2). The exon 1 
encodes N-terminus together with the first TMD and 
the exon 8 encodes TMD 10. The other SLC22A3 
exons encode more than one TMDs (Wieland et al., 
2000). SLC22A3 displays a structure conserved in 
members of solute carrier proteins (OCT1, OCT2, 
ORCTL2, ORCTL3, ORCTL4; Wieland et al., 2000) 
and in different organisms (rat, murine, mouse, and 
human; Burckhardt& Wolff, 2000; Wieland et al., 
2000). 
Transcription 
It is reported that a large noncoding RNA (ncRNA), 
Air, silences cis-linked distal paternal Slc22a3 gene 
(mouse SLC22A3 gene) allele-specifically by 
interacting Slc22a3 promoter and H3K9 histone 
methyltransferase in placenta (Nagano et al, 2008). 
Studies indicate that the basal promoter of SLC22A3 
contains a large CpG island which extends into exon 
1, and abnormal methylation decreases SLC22A3 
expression in human prostate cancer (Chen et al., 
2013). 
Protein 
Description 
The SLC22A3 protein is composed of 551 amino 
acids with a 61 kDa molecular mass (Kekuda et al., 
1998). The protein is predicted to be composed of 12 
TMDs and both NH2 and COOH termini of the 
protein locate at the cytoplasmic site of the plasma 
membrane (Kekuda et al., 1998; Burckhardt Wolff, 
2000). There are three potential N-linked 
glycosylation sites (positions 72, 99 and 114) within 
a large extracellular loop (106 amino acids) located 
between TMDs 1 and 2. Another N-linked 
glycosylation site is localized at position 199 in an 
extracellular loop formed between TMDs 3 and 4. 
SLC22A3 also contains putative phosphorylation 
sites for protein kinase C (Ser-286, Thr-292 and Thr-
459) and protein kinase A (Thr-346 and Thr-544) 
(Kekuda et al., 1998). 
Expression 
SLC22A3 is expressed in a wide range of tissues 
including the first-trimester and term placenta, 
skeletal muscle, prostate, liver, aorta, fetal lung, 
salivary gland, adrenal gland (Verhaagh et al., 1999), 
sympathetically innervated tissues (Lazar et al., 
2003), heart, brain (Vialou et al., 2004; Chen et al., 
2010), central nervous system (Zhu et al., 2012) and 
kidney (Wu et al., 2000). 
Localisation 
SLC22A3 is localized on the plasma membrane 
(Kekuda et al., 1998; Burckhardt Wolff, 2000). 
Function 
SLC22A3 is a potential-sensitive organic cation 
transporter and activated by inside-negative 
membrane potential (Kekuda et al., 1998). The main 
function of the protein is to uptake and to eliminate 
clinically used drugs, endogenous organic cations 
(dopamine, norepinephrine and histamine; Wu et al., 
2000) and toxic substances in the kidney, placenta 
and liver by uptake-2 transport system, which is the 
high-capacity and low-affinity transport system 
(Hayer-Zillgen et al. 2002; Vialou et al., 2004; 
Sakata et al., 2010). SLC22A3 uptakes 
catecholamines and neurotoxic organic cations in 
glial cells (Wieland et al., 2000). It also carries out 
the clearance of monoamines by co-localizing with 
other enzymes in placenta (Verhaagh et al., 2001). 
The mouse homolog Slc22a3 is shown to be 
involved in regulating salt-uptake (Vialou et al., 
2004) and is a regulator of neurotransmission by 
controlling the transportation of dopamine, 
norepinephrine, 5-hydroxytriptamine, epinephrine 
and histamine  in the central nervous system (Zhu et 
al., 2012).  
The activity of SLC22A3 is selectively inhibited by 
corticosterone, progesterone and 17?-estradiol, O-
methylisoprenaline (OMI) and decynium22 (Hayer-
Zillgen et al., 2002). 
Homology 
SLC22A3 shares homology with the other members 
of organic cation transporter OCT1 and OCT2; at 
amino acid sequence level, the identity ranges 
between 30-51% (Kekuda et al., 1998). SLC22A3 
also shows conserved amino acid sequences in 
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mammals (Burckhardt& Wolff, 2000; Wu et al., 
2000). 
Mutations 
It is reported that there are six single-nucleotide 
substitutions and one deletion within the core 
promoter, exonic and intronic sequences and 3' 
untranslated region without any amino acid changes 
in Caucasians, suggesting that the mutations would 
be as the result of demographic differences (Lazar et 
al., 2003).  
A non-synonymous substitution in SLC22A3 gene, 
Mel370Ile, may be related to obsessive-compulsive 
disorder (Lazar et al., 2008).  Of the reported five 
nonsynonymous SNPs (T44M, A116S, T400I, 
A439V and G475S; NCBI dbSNP, 
http://ncbi.nlm.nih.gov/SNP; Sakata et al., 2010), 
A116, A439 and G475 are found only in the 
SLC22A3 gene while the others are also found in 
other organic cation transporter genes. The 
variations in the amino acid sequence result in a 
reduced substrate uptake and functionality (Sakata et 
al., 2010). 
It is also reported that T44M, P84P, A116S, R102R, 
T400I, A411A, L498L SNPs in the coding regions 
of SLC22A3, as well as SNPs in intronic regions, 
may result in alterations in substrate specificity 
(Chen et al., 2010). 
Implicated in 
Hepatocellular carcinoma 
SLC22A3, as SLC22A1, is downregulated in human 
hepatocellular carcinoma.  
The downregulation of SLC22A3 is associated with 
tumor progression and poor patient survival (Heise 
et al. 2012). 
Prostate cancer 
Studies with 12 known risk polymorphisms in risk 
allele status for prostate tissue suggest that 4 of 12 
prostate cancer risk variants are related to five 
transcripts, one of which is SLC22A3.  
Studies suggest that the expression of SLC22A3 is 
reduced in prostate cancer cells due to the aberrant 
methylation of the promoter region, an indication 
that the reduced level of SLC22A3 expression may 
be involved in the progression of prostate cancer 
(Chen et al., 2013). 
Renal cell carcinoma 
Kidneys are important for the excretion of 
xenobiotic compounds and consequently are highly 
susceptible for tumor development.  
Renal cell carcinomas are mainly resistant to 
chemotherapies, which appear to be dependent upon 
the expression of transporter proteins that include 
SLC22A3 (Shnitsar et al., 2009). 
Distal colon cancer 
Genome-wide studies suggest that the genetic 
variant rs7758229 in SLC22A3 is associated with 
colorectal cancer susceptibility in Japanese 
population (Cui et al, 2011), the same variant, on the 
other hand, shows no association for colorectal 
cancer risk in a Chinese cohort (Zhu et al., 2013). 
Coronary artery disease (CAD) 
Genome-wide haplotype association studies suggest 
that SLC22A3-LPAL2-LPA gene cluster constitutes 
a strong susceptibility locus for CAD (Tregouet et 
al., 2009). 
Methamphetamine (MAP) use 
disorder 
MAP is an amphetamine derivative and illicit 
psycho-stimulant. MAP dependence, an important 
social problem, is thought to be influenced by 
genetic factors. Due to the ability of SLC22A3 to 
transport MAP (Wu et al., 1998), it is suggested that 
polymorphisms in SLC22A3 gene may be correlated 
with MAP dependence (Aoyama et al., 2006). 
Obsessive-compulsive disorder 
(OCD) 
OCD is primarily linked with abnormalities in 
serotonergic system. The observations that genome-
wide linkage of OCD (6q26) overlaps with 
SLC22A3 (6q26-q27) provides a support for a role 
of SLC22A3 in OCD. Two novel mutations, 
Met370Ile and -106/107delAG which cause 40% 
reduction in norepinephrine transport in patients, 
could underlie the modulatory role of SLC22A3 in 
OCD (Lazar et al., 2008). 
Depression 
Clearance of neurotransmitters for the 
homeodynamic regulation of the central nervous 
system is mediated by uptake-1 and uptake-2 
systems. The uptake-2 is a low-affinity and high-
capacity system within which SLC22A3 plays a 
significant role (Schildkraut and Mooney, 2004). 
SLC22A3 transports various neurotransmitters 
including dopamine, norepinephrine, epinephrine, 5-
hydroxytryptamine and histamine (Wu et al., 2000). 
Anti-depressants currently used in clinics include 
selective 5-HT and 5-HT-NE inhibitors.  Studies 
suggest that the inhibition of SLC22A3-mediated 
neurotransmitter uptake is a critical contributor for 
the effects of antidepressants, underlying the 
importance of SLC22A3 in depression progression 
and protection (Baganz et al., 2008; Mooney et al., 
2008; Zhu et al., 2012). 
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